A Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast Cancer

Summary

Single arm phase II study for with primary objective to evaluate the efficacy of PLX038 on response rate for patients with pretreated, metastatic or locally advanced triple negative breast cancer.

Timeline

Start

2024-04-17

Primary completion

2025-05-15

Completion

2025-05-15

Outcome

Outcome not reported

Stopped: “No signal of significant toxicity and no signal of activity in the population of the TOPOLGY study”

Drugs

Indications